Kaminski HJ - Search Results

1

Serum metabolomics of treatment response in myasthenia gravis.

Sikorski P, Li Y, Cheema M, Wolfe GI, Kusner LL, Aban I, Kaminski HJ. Sikorski P, et al. Among authors: kaminski hj. PLoS One. 2023 Oct 10;18(10):e0287654. doi: 10.1371/journal.pone.0287654. eCollection 2023. PLoS One. 2023. PMID: 37816000 Free PMC article. Clinical Trial.

2

Differential susceptibility of the ocular motor system to disease.

Kaminski HJ, Richmonds CR, Kusner LL, Mitsumoto H. Kaminski HJ, et al. Ann N Y Acad Sci. 2002 Apr;956:42-54. doi: 10.1111/j.1749-6632.2002.tb02807.x. Ann N Y Acad Sci. 2002. PMID: 11960792 Review.

3

Susceptibility of ocular tissues to autoimmune diseases.

Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L. Kaminski HJ, et al. Ann N Y Acad Sci. 2003 Sep;998:362-74. doi: 10.1196/annals.1254.043. Ann N Y Acad Sci. 2003. PMID: 14592898

4

Molecular architecture of the neuromuscular junction.

Hughes BW, Kusner LL, Kaminski HJ. Hughes BW, et al. Among authors: kaminski hj. Muscle Nerve. 2006 Apr;33(4):445-61. doi: 10.1002/mus.20440. Muscle Nerve. 2006. PMID: 16228970 Review.

5

Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.

Kaminski HJ, Kusner LL, Richmonds C, Medof ME, Lin F. Kaminski HJ, et al. Exp Neurol. 2006 Dec;202(2):287-93. doi: 10.1016/j.expneurol.2006.06.003. Epub 2006 Jul 20. Exp Neurol. 2006. PMID: 16859686

6

Ocular myasthenia: diagnosis, treatment, and pathogenesis.

Kusner LL, Puwanant A, Kaminski HJ. Kusner LL, et al. Among authors: kaminski hj. Neurologist. 2006 Sep;12(5):231-9. doi: 10.1097/01.nrl.0000240856.03505.b5. Neurologist. 2006. PMID: 16990734 Review.

7

Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Soltys J, Gong B, Kaminski HJ, Zhou Y, Kusner LL. Soltys J, et al. Among authors: kaminski hj. Ann N Y Acad Sci. 2008;1132:220-4. doi: 10.1196/annals.1405.037. Ann N Y Acad Sci. 2008. PMID: 18567871 Free PMC article.

8

Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone.

Newsom-Davis J, Cutter G, Wolfe GI, Kaminski HJ, Jaretzki A 3rd, Minisman G, Aban I, Conwit R. Newsom-Davis J, et al. Among authors: kaminski hj. Ann N Y Acad Sci. 2008;1132:344-7. doi: 10.1196/annals.1405.014. Ann N Y Acad Sci. 2008. PMID: 18567886 Clinical Trial.

9

The MGTX experience: challenges in planning and executing an international, multicenter clinical trial.

Aban IB, Wolfe GI, Cutter GR, Kaminski HJ, Jaretzki A 3rd, Minisman G, Conwit R, Newsom-Davis J; Mgtx Advisory Committee. Aban IB, et al. Among authors: kaminski hj. J Neuroimmunol. 2008 Sep 15;201-202:80-4. doi: 10.1016/j.jneuroim.2008.05.031. J Neuroimmunol. 2008. PMID: 18675464 Free PMC article.

10

Novel complement inhibitor limits severity of experimentally myasthenia gravis.

Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ. Soltys J, et al. Among authors: kaminski hj. Ann Neurol. 2009 Jan;65(1):67-75. doi: 10.1002/ana.21536. Ann Neurol. 2009. PMID: 19194881 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

182 results

Search Page